Cipla
Lupin, Glenmark, JB chemicals, Cipla, Aurobindo potential winners to ride $183 bn cardiac therapy market
Thu, Sep 30, 2021
Cardiovascular disease (CVD) is the leading cause of mortality and accounts for one-third of global deaths. Cardiac has displaced anti-infectives as the leading therapy in the India Pharma Market (IPM).
More >
Nifty Pharma set for 14,600 levels - 3 stocks to buy on Wednesday for gains, says Centrum Broking analyst
Wed, Sep 29, 2021
Sun Pharmaceuticals – The shares of Sun Pharma today ended at Rs 790.50 on Tuesday, up 3.6 per cent from the Monday closing price. He puts target price at Rs 850-Rs 880 with a stop loss at Rs 755. The stock has seen some correction after attaining a 52-week high of Rs 804.35 on 3 August
More >
Stocks to Buy on Monday – Cipla, Vardhman Textiles, Poly Medicure are intraday F&O, cash market, positional picks for these targets
Sun, Sep 19, 2021
Sandeep Jain recommends Cipla as an intraday pick on Monday. This is from the F&O segment. This stock was recommended at Rs 954. He puts the target price at Rs 965 while the stop loss at Rs 947
More >
Cipla shares hit NEW HIGH as DCGI approves to import Moderna’s Covid vaccine – check what analyst suggests for the stock investors
Wed, Jun 30, 2021
As Drugs Controller General of India (DCGI) allowed Cipla to import Moderna’s Covid-19 vaccine, the shares of the pharma major hit a new 52-week high of Rs 997.20 after rallying almost two per cent on the BSE intraday trade on Wednesday. The stock has surged around four per cent since Monday.
More >
Stock Markets CLOSING BELL! BSE Sensex, NSE Nifty 50 close in red; Power Grid, Nestle, Cipla among top gainers; bank, IT, metal stocks fall
Tue, Jun 29, 2021
Stock Markets ended in the red on Tuesday. The BSE Sensex closed at 52,567.30 today, down by over 168 points or 0.3 per cent. Meanwhile, the broader Market NSE Nifty 50 ended at 15,748.45, down by 66 points or 0.4 per cent
More >
Top Stocks to Buy – Amid high market volatility, analyst Sandeep Jain recommends Cipla, Timken India, KEC International for bumper returns
Sun, Jun 20, 2021
The stock markets on Friday traded with high volatility. The markets opened without much noise and then fell steeply. Nifty 50 had a free fall and touching around levels of 15,450 on the intraday basis which was a crucial level. The previous lifetime was 15,431 and the markets took a support at this level. Market Analyst Sandeep Jain said that last trading session of the week was extremely action packed.
More >
Cipla will maintain its EBITDA at 22% in FY22, says Kedar Upadhye
Thu, May 20, 2021
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Swati Khandelwal, Zee Business.
More >
Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye
Wed, May 19, 2021
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Zee Business Executive Swati Khandelwal
More >
Cipla share price up nearly 2% despite weak markets: Sharekhan maintains Buy, price target of Rs 1100
Wed, May 19, 2021
Cipla share price: Sharekhan says that Cipla Limited reported strong numbers for Q4FY2021 yoy, though it missed estimates. Results reflect a one time adjustments in gross margins to the tune of 200 bps on account of inventory adjustment for gAlbuterol and charge on material cost inventories. Revenue, at Rs 4606.5 cr, grew by 5% yoy, driven by a 17% rise in US revenues; sales from emerging markets and India grew by 4% yoy each
More >
Cipla Q4 below street estimates: Know what brokerage firms have to say – check target price here
Mon, May 17, 2021
Amid the fourth quarter results being sharply below estimates, the brokerage firms post mixed sentiments towards the pharma major Cipla. However, the company reported a 68 per cent jump in the consolidated net profit in the March-ended quarter of the financial year 2020-2021.
More >
Cipla share price: Sharekhan maintains Buy recommendation with price target of Rs 1100
Mon, May 17, 2021
Cipla share price: Sharekhan says that Cipla Limited reported strong numbers for Q4FY2021 yoy, though it missed estimates. Results reflect a one time adjustments in gross margins to the tune of 200 bps on account of inventory adjustment for gAlbuterol and charge on material cost inventories. Revenue, at Rs 4606.5 cr, grew by 5% yoy, driven by a 17% rise in US revenues; sales from emerging markets and India grew by 4% yoy each
More >
Cipla Q4FY21 net profit up 73% at Rs 412 cr; company board recommends Rs 5 dividend for FY21
Fri, May 14, 2021
Drug major Cipla on Friday today posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets. The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20
More >
Cipla, Cadila Healthcare, Glenmark Pharma: Technicals highlighted by Bonanza Portfolio
Mon, Apr 19, 2021
Vishal Wagh, Research Head at Bonanza Portfolio says that Nifty pharma has shown consistent outperformance to the major indices and the current pandemic environment is creating a large demand for the sector. He said that as per ranking based on its performance against the NIFTY and Nifty Pharma, Cadila, Glenmark, Cipla, Sun pharma, Divislab, Auropharma, Lupin and Dr Reddy will outperform in the sector whereas, Biocon, Alkem, APL and Granules may underperform
More >
Cipla shares hit new high; Sharekhan pegs target at Rs 1100 as Pharma giant doubles Remdesivir production
Sat, Apr 17, 2021
The Pharma Sector has been in focus and many analysts are recommending buying into this sector on the back of Covid issues resurfacing in India. Increase in the production of Vaccines will benefit many Pharma companies including Cipla.
More >
Cipla is the TOP gainer on Nifty today; expert pegs price target between Rs 950-Rs 1000 going forward
Mon, Apr 12, 2021
Even as wider markets were down in a significant manner, Cipla share price today rose to Rs 915, up Rs 32 or 3.6%. Cipla share price has moved from Rs 837 to Rs 915 over the last week. Cipla share price topped the Nifty Gainers list on Friday as well. The stock is seeing good buying as revenues of the company is going to increase going forward on increasing Covid worries
More >
Cipla is top GAINER on Nifty today, expert says BUY this share with price target of Rs 978
Fri, Apr 09, 2021
Cipla share price closed at Rs 883, up Rs 41 or 4.9%. Cipla moved from Rs 817 to Rs 883 in this week. Kotak Institutional Equities said that Lannett’s announcement of ANDA filing for Advair, a key pipeline product for Cipla, is in line with expectations and they see limited impact on Cipla’s Advair opportunity
More >
